Metabolic therapy in children with hypotensive type of autonomic dysfunction syndrome
Journal Title: Здоров`я дитини - Year 2018, Vol 13, Issue 7
Abstract
Background. Trimetabol is a combined appetite stimulant that has cardioprotective, neurotropic and antioxidant effects. The purpose was to evaluate the effectiveness of metabolic therapy with the use of Trimetabol in children with hypotensive type of autonomic dysfunction syndrome. Materials and methods. Forty five children aged 9–17 years with autonomic hypotensive dysfunction were examined. All children were divided into two groups: the main group (n = 30) received Trimetabol, the comparison group (n = 15) — multivitamins. The course of treatment was 1 month. Results. Against the background of treatment with Trimetabol, headache, dizziness, heart pain decreased, appetite, heart rhythm and conduction normalized. Unlike the comparison group, the children of the main group experienced better dynamics of ambulatory blood pressure monitoring (ABPM) and heart rate variability. According to ABPM, average daily systolic blood pressure (SBP) increased from 107.4 ± 1.0 mmHg to 110.8 ± 1.1 mmHg, p < 0.05 (in the comparison group, it has not changed significantly), the time index of hypotension of SBP decreased from 36.3 ± 2.9 % to 25.4 ± 2.6 %, p < 0.01 (in the comparison group — from 40.7 ± 4.7 % to 26.8 ± 4.6 %, p < 0.05). Reduction in total spectrum power was observed in both groups, but in the main group, it was more significant and occurred as a result of a decrease in VLF% (from 75.82 ± 1.63 % to 69.50 ± 1.70 %, p < 0.05), and due to an increase in the specific gravity of LF (from 8.78 ± 0.43 % to 10.20 ± 0.37 %, p < 0.05) and HF% (from 11.31 ± 0.46 % to 13.90 ± 0.80 %, p < 0.05). These data indicate that under the influence of Trimetabol, the central and autonomic regulation circuit activity was redistributed from the decrease in the activity of the central circuits (VLF%) and the relative increase in the activity of autonomic circuits (LF%, HF%). Conclusions. Trimetabol is an effective drug for the treatment of hypotensive type of autonomic dysfunction. The use of Trimetabol improves metabolic processes in the myocardium, normalizes the autonomic regulation of the cardiac rhythm and blood pressure and is safe for adolescents.
Authors and Affiliations
Yu. V. Marushko, T. V. Hyshchak
Keywords
Related Articles
- EP ID EP423722
- DOI 10.22141/2224-0551.13.7.2018.148920
- Views 95
- Downloads 0
Substantiation for Rational Antibacterial Therapy of Respiratory Bacterial Diseases in Children
This article discusses the current state of the problem of antibiotic therapy for bacterial respiratory infections in children. The use of third generation cephalosporin — cefpodoxime proxetil (Cefodox) in respiratory di...
Didactic Approaches to the Teaching Pharmacotherapy in Pediatrics
Clinical reasoning formation is impossible without correct organization of the teaching process. Aim of the study was to indicate didactic approaches to teaching pharmacotherapy to students in pediatrics, to define metho...
Clinical and Experimental Characteristics of Amizon and Experience of its Use in Clinical Practice
The analysis of the data on the study of Amizon is presented in this article. Information about its properties obtained during experiments in vitro and clinical investigations is provided. Pharmacodynamic and clinical fe...
Chronic Granulomatous Disease: the Experience of Diagnosis and Treatment in Children
Chronic granulomatous disease — primary immunodeficiency with X-linked and autosomal recessive inheritance, characterized by impaired bactericidal function of phagocytic immune system. Chronic granulomatous disease is ac...
Modern aspects of conservative therapy for urinary incontinence and preservation of renal function in children with spina bifida
Congenital neural tube defects are one of the most common congenital malformations, in which several organs and systems are affected. Due to the improvement of surgical treatment, the survival of these patients has incre...